Systemic administration of a core peptide of HspB5 in ischemic hypoxic conditions prevented RGC loss in rat retinal explants ex vivo and in vivo. It inhibited RGC axons and soma degeneration in rodent models of glaucoma (Stankowska et al., 2019). This evidence concerns the gene CRYAB and glaucoma.